Back

FXa promotes endothelial dysfunction and pro-remodeling responses in atrial endothelial cells involving PAR1 and 2 and AT1R/NADPH oxidase/SGLT1/2 pro-oxidant pathways

21 May 2022 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: New therapeutic approaches for heart failure Drugs, Drug Targets HFA Premium Access Heart Failure 2022

About the speaker

Photo
Doctor Walaa Fakih

Strasbourg (France)

4 More presentations in this session

Presentation thumbnail
Repurposing of glatiramer acetate to treat cardiac ischemia
Doctor G. Aviel (Rehovot, IL)
Abstract Slides Video
Presentation thumbnail
Repeated low doses of doxorubicin induce senescence and functional decline in dyn-EHTs which can be rescued using senomorphics.
Ms A. Linders (Groningen, NL)
Abstract Slides Video
Presentation thumbnail
Living myocardial slices for the study of nucleic acid-based therapies
Doctor R. Nunez-Toldra (London, GB)
Abstract Slides Video
Presentation thumbnail
Identification and characterization of small-molecule ERBB4 agonists as a treatment for heart failure
Miss E. Feyen (Antwerp, BE)
Abstract Slides Video

Access the full session

Session thumbnail
New therapeutic approaches for heart failure
Video

The Event

Event poster

Heart Failure 2022

21 May - 24 May 2022

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources